Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial

@article{Solomon2007EffectOA,
  title={Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial},
  author={Scott D. Solomon and Rajesh Janardhanan and Anil Verma and Mikhail Bourgoun and William Lionel Daley and D. Das Purkayastha and Yves Lacourci{\'e}re and Stephen Hippler and Harold Fields and Tasneem Z Naqvi and Sharon L. Mulvagh and J. Malcolm O. Arnold and James D. Thomas and Michael R. Zile and Gerard P Aurigemma},
  journal={The Lancet},
  year={2007},
  volume={369},
  pages={2079-2087}
}
BACKGROUND Diastolic dysfunction might represent an important pathophysiological intermediate between hypertension and heart failure. Our aim was to determine whether inhibitors of the renin-angiotensin-aldosterone system, which can reduce ventricular hypertrophy and myocardial fibrosis, can improve diastolic function to a greater extent than can other antihypertensive agents. METHODS Patients with hypertension and evidence of diastolic dysfunction were randomly assigned to receive either the… 
Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients.
  • N. Toh, K. Ishii, +4 authors Hiroshi Ito
  • Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2016
TLDR
The combination of losartan and HCTZ is as effective as amlodipine plus ARB in improving LV relaxation in hypertensive patients, and improvement in LV relaxation was similar between the groups.
Adding thiazide to a renin–angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension
TLDR
Changing from an ACEi or ARB to a combination of losartan and hydrochlorothiazide (HCTZ) on left ventricular preload and relaxation in patients with hypertension and diastolic dysfunction is associated with a reduction in BP, improvement in LV relaxation, improved in heart failure state and attenuation of systemic inflammation with few adverse effects.
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy
TLDR
Aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy, and reduction in LV mass with the combination of aliskiren plus losartan was not significantly different from that withLosartan monotherapy, independent of blood pressure lowering.
Role of the renin-angiotensin-aldosterone system in diastolic dysfunction and heart failure 1
TLDR
In patients with LV hypertrophy, diastolic dysfunction or heart failure blood pressure should be tightly controlled by medical treatment usually including an ACE inhibitor or AT1 receptor antagonist although to date prognosis was not shown to be improved by RAAS inhibition in randomised studies.
Effect of Intensive Versus Standard Blood Pressure Lowering on Diastolic Function in Patients With Uncontrolled Hypertension and Diastolic Dysfunction
TLDR
The degree of improvement in annular relaxation velocity was associated with the extent of systolic blood pressure reduction, and patients with the lowest achieved systolics blood pressure had the highest final diastolic relaxation velocities.
Treatment of diastolic dysfunction in hypertension.
  • P. Ginelli, J. Bella
  • Medicine
    Nutrition, metabolism, and cardiovascular diseases : NMCD
  • 2012
TLDR
The Trial Of Preserved Cardiac function heart failure with an Aldosterone anTagonist (TOPCAT) is an on-going large, international study evaluating the effect of spironolactone on cardiovascular mortality, aborted cardiac arrest, or hospitalization for diastolic heart failure.
Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease
TLDR
In patients with hypertensive heart disease and normal left ventricular ejection fraction, abnormalities inleft ventricular mechanical systolic function can be ameliorated in the setting of targeted antihypertensive treatment.
The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function and Atherosclerosis in Japanese Patients with Mild-to-Moderate Hypertension (J-ELAN) study
TLDR
Losartan may improve LV diastolic function, and amlodipine may attenuate LV hypertrophy; however, this study cannot make consecutive remarks about the superiority of either treatment regimen in the effects on cardiac function and geometry.
Reverse remodeling and improved function by antihypertensive treatment in hypertensive patients with coronary artery disease
TLDR
Treatment with nifedipine retard or ACE-Is cause a comparable change in remodeling and cardiac function, and there is a favorable effect on the left ventricular structure and function.
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension
TLDR
Looking at the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension, it is found that this drug improves myocardIAL function independent of BP reduction in hypertensive patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.
TLDR
The VALIDD Trial is an investigator-initiated randomized, controlled, double-blind clinical trial designed to explore whether antihypertensive therapy with the ARB valsartan, in addition to standard therapy, would improve intrinsic diastsolic properties of the myocardium in patients with hypertension and evidence of diastolic dysfunction.
Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
TLDR
Antihypertensive therapy resulting in LV mass or relative wall thickness regression is associated with significant improvement of diastolic filling parameters related to active relaxation and passive chamber stiffness compared with patients without regression, independent of BP reduction; however, abnormalities of diastsolic LV filling remain common.
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
TLDR
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination.
Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease
TLDR
In patients with hypertensive heart disease, angiotensin-converting enzyme inhibition with lisinopril can regress myocardial fibrosis, irrespective of LVH regression, and it is accompanied by improved LV diastolic function.
Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment
TLDR
Directionally opposite changes in isovolumic relaxation time (IVRT) and deceleration time indicate improvement in active LV relaxation and passive chamber stiffness during early diastole.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
TLDR
Cedesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%.
Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.
TLDR
In this first meta-analysis including only double-blind, randomized, controlled clinical studies, decline in blood pressure, duration of drug treatment, and drug class determined the reductions in left ventricular mass index.
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
TLDR
Codesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure and there was no significant heterogeneity for candesartan results across the component trials.
Intracardiac Angiotensin‐Converting Enzyme Inhibition Improves Diastolic Function in Patients With Left Ventricular Hypertrophy due to Aortic Stenosis
TLDR
Intracoronary enalaprilat at a dosage that did not cause systemic neurohormonal activation improved LV diastolic chamber distensibility and regional relaxation and filling in patients with LV hypertrophy due to aortic stenosis.
Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial
TLDR
Antihypertensive treatment with losartan, plus hydrochlorothiazide and other medications when needed for pressure control, resulted in greater LVH regression in patients with ECG LVH than conventional atenolol-based treatment, indicating angiotensin receptor antagonism byLosartan has superior efficacy for reversing LVH, a cardinal manifestation of hypertensive target organ damage.
...
1
2
3
4
5
...